8-K current report · filed Jul 29, 2026

LB PHARMACEUTICALS INC (LBRX) 8-K Current Report: July 29, 2026

Item EX-99.1Item 1.01Item 7.01Item 3.02LBRX overview

Short answer

LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 3.02 (Unregistered Sales of Equity Securities). Private placement targeting approximately $150.0 million gross proceeds, strengthening funding for LB-102 development and corporate needs.

LB PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Private placement targeting approximately $150.0 million gross proceeds, strengthening funding for LB-102 development and corporate needs
  • Issuance of 3,577,560 common shares plus pre-funded warrants for 715,513 shares, creating immediate dilution and potential additional dilution
  • Financing supports expansion into schizophrenia negative symptoms and Alzheimer’s agitation/psychosis, with potential trial initiation in the second half of 2027
  • Pre-funded warrants exercisable immediately at $0.0001 per share, with no expiration and 4.99% or 9.99% ownership caps
  • Resale registration required within 90 days of closing, potentially increasing future tradable share supply

Item 3.02 · Unregistered Sales of Equity Securities

  • Private placement shares issued under Securities Act Section 4(a)(2) exemption
  • Restricted securities, not registered for public resale
  • Transaction limited to investors providing private-placement representations
  • Potential future dilution and resale overhang for existing shareholders

Item 7.01 · Regulation FD Disclosure

  • July 29, 2026 press release announces a private placement
  • Financing likely provides capital for corporate purposes, with dilution and funding terms requiring review of Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • $150 million private placement at $34.94 per share, supporting LB-102 development and corporate funding
  • 3,577,560 shares plus pre-funded warrants for 715,513 shares, creating material potential dilution
  • Proceeds targeted at LB-102 expansion into schizophrenia negative symptoms and Alzheimer’s agitation or psychosis
  • Financing includes new and existing institutional investors, strengthening near-term funding for ongoing Phase 3 and Phase 2 trials
  • Resale registration rights may increase future trading supply once registration becomes effective

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LB PHARMACEUTICALS INC 8-K filings

Get the next LBRX 8-K as it lands

Follow LBRX for push alerts, or ask the research agent what this filing means.